Optimizing continuous ECG monitoring in clinical trials
The importance of continuous ECG monitoring in clinical trials
Authors:
- Vickas Patel, M.D., Ph.D. – VP and Chief Medical Officer, Cardiology at Clario, part of Thermo Fisher Scientific
- Todd Rudo, M.D. – Chief Medical Officer at Clario, part of Thermo Fisher Scientific
- Olga Bokeriya, M.D., Ph.D. – Senior Cardiologist and ECG Core Director at Clario, part of Thermo Fisher Scientific
- Alain Gay, M.D. – Senior Cardiologist, Cardiology at Clario, part of Thermo Fisher Scientific
Summary
Continuous electrocardiography (ECG) monitoring plays a critical role in evaluating cardiac safety and efficacy in clinical trials. While standard 12-lead ECGs capture only a brief snapshot of cardiac electrical activity, continuous monitoring solutions can identify arrhythmias and cardiac events that occur outside scheduled study visits.
Why continuous ECG monitoring matters
Cardiac monitoring is a fundamental component of many clinical development programs, particularly when evaluating investigational therapies that may affect heart rhythm, cardiac conduction, or cardiac repolarization. Standard 12-lead ECGs provide valuable information but are limited to a brief recording period and may miss intermittent or rare arrhythmias.
Continuous ECG monitoring allows sponsors and researchers to:
- Detect infrequent cardiac arrhythmias
- Measure arrhythmia burden and event frequency
- Assess treatment efficacy for antiarrhythmic therapies
- Support cardiac safety monitoring throughout a study
- Capture clinically significant events occurring between study visits
- Generate more comprehensive cardiovascular endpoint data
Key ECG monitoring technologies
As clinical trial designs continue to evolve, selecting the appropriate ECG monitoring strategy has become increasingly important for balancing patient safety, operational efficiency, and data quality.
This expert-authored white paper provides guidance on:
- Selecting the most appropriate continuous ECG monitoring modality for clinical trials
- Understanding the differences between Holter monitors, patch monitors, MCOT systems, and inpatient telemetry
- Determining when near real-time remote ECG monitoring is needed
- Evaluating monitoring duration requirements
- Understanding best practices for QT interval measurements
- Improving participant compliance and monitoring effectiveness
- Matching monitoring technology to trial objectives and cardiac safety requirements
Inpatient telemetry
Inpatient telemetry provides real-time cardiac monitoring for participants at risk of life-threatening arrhythmias or other serious cardiac events requiring immediate intervention. This approach supports continuous surveillance by trained personnel and enables rapid response to critical cardiac safety signals.
Mobile Cardiac Outpatient Telemetry (MCOT)
MCOT systems are designed for remote cardiac monitoring outside the clinical setting. These devices automatically detect and transmit arrhythmia events to centralized monitoring centers, allowing near real-time review and notification of clinically significant findings. MCOT can support extended outpatient monitoring while maintaining an added layer of cardiac safety oversight.
Holter ECG monitoring
Holter monitors remain one of the most widely used tools for continuous ECG monitoring in clinical research. High-fidelity 12-lead Holter recordings enable extraction of ECGs for precise interval analysis, including QT assessments. Holter monitoring is particularly valuable when intensive cardiac safety evaluations are required, or higher resolution is needed to differentiate a trial event from ventricular events.
Patch monitors
Patch-based ECG monitoring systems deliver extended monitoring durations with minimal participant burden. Their lightweight design, ease of wear, and longer recording periods can improve compliance and increase the likelihood of detecting infrequent arrhythmias. Patch monitors are particularly useful for outpatient studies requiring monitoring over seven to fourteen days.
Handheld ECG Solutions
Portable ECG devices such as handheld monitors offer a convenient method for intermittent remote cardiac assessment. These solutions can complement traditional clinic-based ECG collections and support decentralized or hybrid clinical trial models while maintaining cardiac safety surveillance.
Why this matters for sponsors
01
Improved safety monitoring
Continuous ECG monitoring enhances detection of cardiac safety signals and supports participant protection throughout drug development.
02
Better arrhythmia detection and quantification
Extended ECG monitoring can improve identification and measurement of arrhythmia burden, frequency, and duration.
03
Remote and decentralized monitoring
Wearable and remote ECG technologies support modern clinical trial models while improving participant experience and operational flexibility.
Explore the full white paper
Get the complete white paper today or click get started to continue the conversation.
